According to the results announced at the 2018 ASCO annual meeting, the CDK4/6 inhibitors pabociclib (Ibrance) and cetuximab (Erbitux) combined treatment of platinum-resistant and HPV-independent recurrent/metastatic head and neck The overall response rate for patients with squamous cell carcinoma (HNSCC) is 39%. In a non-randomized, 3-arm, phase II trial (NCT02101034), the results of a group of studies have a median progression-free survival (PFS) of 5.4 months, a median overall survival (OS) of 9.5 months, and a 1-year OS The rate is 35%.
In this study, 30 patients with HNSCC unrelated to HPV progressed after platinum-based therapy for relapsed/metastatic disease and participated in the trial. Patients who had previously received cetuximab for relapse and HPV-related oropharyngeal cancer were not eligible. Patients received palbociclib from day 1 to day 21, 125 mg daily; cetuximab, with a starting dose of 400 mg/m 2 and then 250 mg/m 2 per week for a period of 28 days until the disease progressed or withdrew the study. The researchers performed imaging examinations before treatment and after every 2 cycles.
Pacientu vidējais vecums bija 67 gadi, un audzēja vietas bija mutes dobums (47%), balsene (27%) un orofarneks (13%). 20% pacientu ir lokālas reģionālas metastāzes, 27% ir tālu metastāzes un 53% ir abas. Piecpadsmit (50%) pacienti saņēma ≥ 2 procedūras.
No 28 novērtējamiem pacientiem 11 (39%) bija audzēja atbildes reakcijas, tostarp 3 (11%) pilnīgas atbildes un 8 (29%) daļējas atbildes reakcijas. Četrpadsmit (50%) pacientiem bija stabila slimība, 3 (11%) pacientiem progresēja un 70% bija samazināti audzēja bojājumi.
Researcher Dr. Adkins said that Palbociclib and cetuximab have strong antitumor activity in platinum-resistant HPV-independent head and neck cancer, and biologically targeted therapy for HPV-independent head and neck cancer is an effective treatment strategy. . We look forward to the better results of the follow-up research.
